Funding agency DST

Start date March 29, 2023

End Date None

Duration None

Disease category Gaucher’s disease

Type of study Invito study

Type of data Quantitative data

Aims of objective • Development of Cell Culture Processes, Analytical/bio-analytical characterization methods, Upstream and Downstream Development for Biobetter and Biologics. • The main current treatment option for Gaucher Disease ‘Cerezyme’ costs upwards of INR 40 Lakhs/year/patient and needs to be taken life-long. Aim is 80-90% cost reduction to the patient.

Keyword Biotherapeutics, Gaucher disease, Biobetter, Biologics, Cerezyme

Description None

Total Sanctioned budget None